Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13191)	1/10/1998 7:13:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

Henry--great work. Better for research than any company website I have seen--fulfills a much need function. Just a couple of questions--is there any info available on ALRT268 (probably now LGND 268). Was reading about it in the annual report and it looks highly effective in regard to diabetes, but I know it has not entered clinicals yet. Do you think it will make it this year? Also regarding Targretin, I was rereading the Dec. 16th release on the breast cancer results. Pretty impressive but I can find nothing about Targretin being in trials for breast cancer. This just doesn't make any sense to me. Any ideas? Thanks again for your website efforts--you are doing a terrific job!!